301 related articles for article (PubMed ID: 30997868)
1. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice.
Lahcene H; Aprikian AG; Vanhuyse M; Hu J; Bladou F; Cury F; Kassouf W; Perreault S; Dragomir A
J Oncol Pharm Pract; 2020 Mar; 26(2):293-305. PubMed ID: 30997868
[TBL] [Abstract][Full Text] [Related]
2. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
[TBL] [Abstract][Full Text] [Related]
3. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
Davies RS; Smith C; Lester JF
Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
[TBL] [Abstract][Full Text] [Related]
4. Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Vestris PG; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
Prostate; 2022 Feb; 82(2):269-275. PubMed ID: 34822183
[TBL] [Abstract][Full Text] [Related]
5. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
6. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N
Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
[TBL] [Abstract][Full Text] [Related]
7. Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.
Sonpavde G; Huang A; Wang L; Baser O; Miao R
BJU Int; 2018 Jun; 121(6):871-879. PubMed ID: 29388324
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
[TBL] [Abstract][Full Text] [Related]
9. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.
Okita K; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2020 Apr; 18(2):e103-e111. PubMed ID: 31810867
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Szarvas T; Csizmarik A; Váradi M; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Tschirdewahn S; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
Urol Oncol; 2021 May; 39(5):296.e11-296.e19. PubMed ID: 33046366
[TBL] [Abstract][Full Text] [Related]
14. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
[TBL] [Abstract][Full Text] [Related]
15. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
16. [Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].
Richter I; Dvořák J; Hejzlarová V; Chalupa J; Sochor M; Stankuš I; Barsová L; Holikova M; Forster J; Bartoš J
Klin Onkol; 2016; 29(2):127-32. PubMed ID: 27081803
[TBL] [Abstract][Full Text] [Related]
17. Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer.
Fukuokaya W; Kimura T; Urabe F; Kimura S; Tashiro K; Tsuzuki S; Koike Y; Sasaki H; Miki K; Egawa S
Int J Clin Oncol; 2020 Sep; 25(9):1695-1703. PubMed ID: 32488548
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract][Full Text] [Related]
19. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Lebdai S; Basset V; Branchereau J; de La Taille A; Flamand V; Lebret T; Murez T; Neuzillet Y; Ploussard G; Audenet F
World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956
[TBL] [Abstract][Full Text] [Related]
20. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
Schmid SC; Geith A; Böker A; Tauber R; Seitz AK; Kuczyk M; von Klot C; Gschwend JE; Merseburger AS; Retz M
Adv Ther; 2014 Feb; 31(2):234-41. PubMed ID: 24442834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
